LLY

1,015.45

-0.45%↓

JNJ

245.44

+0.71%↑

ABBV

224.71

-0.94%↓

NVS

163.31

-1.57%↓

MRK

121.02

+0.26%↑

LLY

1,015.45

-0.45%↓

JNJ

245.44

+0.71%↑

ABBV

224.71

-0.94%↓

NVS

163.31

-1.57%↓

MRK

121.02

+0.26%↑

LLY

1,015.45

-0.45%↓

JNJ

245.44

+0.71%↑

ABBV

224.71

-0.94%↓

NVS

163.31

-1.57%↓

MRK

121.02

+0.26%↑

LLY

1,015.45

-0.45%↓

JNJ

245.44

+0.71%↑

ABBV

224.71

-0.94%↓

NVS

163.31

-1.57%↓

MRK

121.02

+0.26%↑

LLY

1,015.45

-0.45%↓

JNJ

245.44

+0.71%↑

ABBV

224.71

-0.94%↓

NVS

163.31

-1.57%↓

MRK

121.02

+0.26%↑

Search

Twist Bioscience Corp

Abierto

SectorSalud

53.24 -6.91

Resumen

Variación precio

24h

Actual

Mínimo

52.83

Máximo

57.73

Métricas clave

By Trading Economics

Ingresos

-3.4M

-31M

Ventas

4.7M

104M

Margen de beneficio

-29.419

Empleados

979

EBITDA

-3.2M

-24M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

-5.32% downside

Dividendos

By Dow Jones

Próximas Ganancias

4 may 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

409M

3B

Apertura anterior

60.15

Cierre anterior

53.24

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

165 / 351 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Twist Bioscience Corp Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

18 feb 2026, 22:31 UTC

Ganancias

Brambles Raises Dividend, Cash-Flow Guidance as 1st Half Profit Jumps -- Update

18 feb 2026, 22:18 UTC

Ganancias

Wal-Mart de Mexico 4Q Profit Falls, Hit by Higher Taxes

18 feb 2026, 22:11 UTC

Ganancias

Wesfarmers Boosts Dividend After 1st Half Profit Rises -- Update

18 feb 2026, 21:52 UTC

Ganancias

Telstra Boosts Dividend as First-Half Earnings Rise 5.5% -- Update

18 feb 2026, 23:56 UTC

Charlas de Mercado

Santos's Review of Domestic Assets Could Lead to Simpler Portfolio -- Market Talk

18 feb 2026, 23:46 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

18 feb 2026, 23:46 UTC

Charlas de Mercado

Nikkei May Rise After U.S. Tech Stock Gains -- Market Talk

18 feb 2026, 23:34 UTC

Charlas de Mercado
Ganancias

Brambles' Cost Control Stands Out to Bull -- Market Talk

18 feb 2026, 23:33 UTC

Charlas de Mercado

Gold Edges Higher Amid Growing Risks of U.S.-Iran Conflict -- Market Talk

18 feb 2026, 23:32 UTC

Charlas de Mercado

Australia Jobs Data Will Likely Support May Hike Assumptions -- Market Talk

18 feb 2026, 22:45 UTC

Ganancias

DoorDash Stock Rebounds. Earnings and Revenue Both Fall Short. -- Barrons.com

18 feb 2026, 22:44 UTC

Charlas de Mercado

Investors Eyeing Nvidia's Revenue Visibility Ahead of 4Q Print -- Market Talk

18 feb 2026, 22:37 UTC

Ganancias

Nutrien 4Q EPS $1.18 >NTR.T

18 feb 2026, 22:37 UTC

Ganancias

Nutrien 4Q Sales $5.34B >NTR.T

18 feb 2026, 22:35 UTC

Ganancias

Pan American Silver 4Q EPS $1.07 >PAAS

18 feb 2026, 22:35 UTC

Ganancias

Pan American Silver 4Q Rev $1.18B >PAAS

18 feb 2026, 22:30 UTC

Ganancias

Kinross Gold Raises Quarterly Dividend to 4c Vs. 3.5c >K.T

18 feb 2026, 22:29 UTC

Ganancias

Kinross Gold 4Q EPS 75c >K.T

18 feb 2026, 22:22 UTC

Ganancias

Coeur Mining: Full-Yr 2026 Production Is Expected to Be 55,000 - 65,000 Ounces of Gold and 5.5M - 6.3M Ounces of Silver >CDE

18 feb 2026, 22:22 UTC

Charlas de Mercado

Nvidia 4Q Earnings Coming Amid China Export Battle -- Market Talk

18 feb 2026, 22:16 UTC

Ganancias

Brambles Raises Dividend, Cash-Flow Guidance as 1H Profit Jumps -- Update

18 feb 2026, 22:05 UTC

Ganancias

Pan American Silver Reports Record Fourth Quarter And Full Year 2025 Financial Results; Record Cash Flow From Operations Of $554 Million In The Fourth Quarter; Dividend Increased By 29% >PAAS

18 feb 2026, 22:03 UTC

Ganancias

Kaiser Aluminum Expects to Improve Conversion Rev by 5% to 10% and Adj EBITDA by 5% to 15% for FY26 >KALU

18 feb 2026, 22:02 UTC

Ganancias

Kaiser Aluminum 4Q Adj EPS $1.53 >KALU

18 feb 2026, 22:02 UTC

Ganancias

Kaiser Aluminum 4Q Sales $929M >KALU

18 feb 2026, 22:02 UTC

Ganancias

Kaiser Aluminum 4Q EPS $1.68 >KALU

18 feb 2026, 22:00 UTC

Ganancias

Kinross Gold 4Q Adj EPS 67c >KGC

18 feb 2026, 22:00 UTC

Ganancias

Kinross Gold 4Q Sales $2.02B >KGC

18 feb 2026, 21:56 UTC

Ganancias

Wesfarmers Boosts Dividend After 1H Profit Rises -- Update

18 feb 2026, 21:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Twist Bioscience Corp Esperado

Precio Objetivo

By TipRanks

-5.32% caída

Estimación a 12 meses

Media 52 USD  -5.32%

Máximo 58 USD

Mínimo 50 USD

De acuerdo con 6 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Twist Bioscience Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

6 ratings

6

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

31.56 / 38.6884Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Bearish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

165 / 351 Clasificación en Salud

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Twist Bioscience Corp

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat